Together, these data highlight important heterogeneities between dysferlinopathies and other types of MD, and stresses the need to assess the safety and efficacy of AngII-dependent therapies in the LGMD2B patient population. Here, DYSF is linked to neuromuscular disease caused by qualitative or quantitative defects of dysferlin.